DSIJ Mindshare

In conversation with Krishna Raghunathan, CFO of Supriya Lifescience Ltd

Today's customers are more informed, and regulatory expectations for quality are higher than ever. Given these factors, I believe the Indian pharmaceutical industry is set for continued growth and global leadership, states Krishna Raghunathan, CFO of Supriya Lifescience Ltd.

Mandar Wagh 0 175 Article rating: 4.2

Today's customers are more informed, and regulatory expectations for quality are higher than ever. Given these factors, I believe the Indian pharmaceutical industry is set for continued growth and global leadership, states Krishna Raghunathan, CFO of Supriya Lifescience Ltd.

DIIs bought 2,33,222 shares: Mukul Agrawal’s portfolio aerospace & defence stock; Revenue surged 21 per cent & PAT rocketed 76 per cent

The stock gave multibagger returns of 575 per cent in 3 years and a whopping 6,825 per cent in 5 years.

Kiran Shroff 0 283 Article rating: 3.5

The stock gave multibagger returns of 575 per cent in 3 years and a whopping 6,825 per cent in 5 years.

RSS
First95969798100102103104Last
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR